Do Tubular Changes in the Diabetic Kidney Affect the Susceptibility to Acute Kidney Injury?

Volker Vallon

Division of Nephrology-Hypertension, Departments of Medicine and Pharmacology, University of California San Diego, and VA San Diego Healthcare System, San Diego, Calif., USA

Key Words
Diabetic nephropathy · Tubular hypothesis · Tubular injury · Regeneration · Clinical studies · Risk factor

Abstract
Diabetes is the single largest contributor to the growing prevalence of chronic kidney disease (CKD), and episodes of acute kidney injury (AKI) increase the risk of advanced CKD in diabetic patients. Here we discuss whether the pathophysiological changes that occur in the tubular system of the diabetic kidney affect the intrinsic susceptibility to AKI. There is abundant data showing that drug-induced nephrotoxicity is attenuated in rodents with experimental diabetes mellitus, and some mechanistic explanations have been provided, in particular in response to aminoglycosides. Besides downregulation in proximal tubular megalin, which mediates the aminoglycoside uptake in proximal tubules, a role for hyperglycemia-induced activation of regenerative mechanisms has been proposed. The available clinical data, however, indicates that diabetes is a risk factor for AKI, including aminoglycoside nephrotoxicity. While much needs to be learned about this disconnect, the isolated induction of diabetes in otherwise healthy young adult rodents may simply not fully mimic the influence that diabetes exerts in the setting of a critically ill and often elderly patient. We speculate that diabetic tubular growth and the associated molecular signature (including upregulation of TGF-β, senescence, and inflammation) set up the development of diabetic nephropathy and renal failure in part by increasing the susceptibility to AKI, which further promotes hypoxia and apoptosis. Considering the strong association between AKI episodes and the cumulative risk of developing advanced CKD in diabetes, strategies that reduce AKI in these patients are expected to help reduce the growing burden of end-stage renal disease.

The Tubular Hypothesis of Glomerular Filtration and Nephropathy in Diabetes

Diabetes is the single largest contributor to the growing prevalence of chronic kidney disease (CKD), and 35% of adults who have diabetes also have CKD [1]. Diabetes mellitus affects the kidney in stages. At the onset, in a subset of diabetic patients the kidneys grow large and the glomerular filtration rate (GFR) becomes supranormal. The tubular hypothesis of glomerular filtration and ne-
Phropathy in diabetes is a pathophysiological concept to explain these changes that puts the tubular system at the center [2, 3] (fig. 1). The concept states that early tubular growth and sodium-glucose cotransport enhance proximal tubular hyperreabsorption, the salt paradox, and glomerular hyperfiltration. The latter promotes inflammation, fibrosis, and tubulointerstitial damage through enhanced glomerular filtration of factors and proteins (including albumin) that interact with the tubular system. The molecular signature of diabetic tubular growth includes senescence, which releases proinflammatory factors. We hypothesize that both tubular growth/senescence and the induced inflammation, fibrosis, and tubulointerstitial damage enhance the susceptibility of the diabetic kidney to episodes of AKI, which promote the development of late consequences including hypoxia, apoptosis, and renal failure. SGLT2 = Sodium glucose cotransporter 2.

**Acute Kidney Injury and the Link to CKD in Diabetes**

Acute kidney injury (AKI) is an established risk factor for CKD. Thakar et al. [4] reported that AKI episodes in diabetic patients are associated with a cumulative risk for developing stage 4 CKD; this applied to all levels of baseline renal function and was independent of other major risk factors of progression, and each AKI episode doubled that risk. Drug-induced nephrotoxicity is responsible for 10–20% of AKI cases [5]. Nephrotoxicity is often the most important limitation for the dosage or intensity of the therapeutic regimen and may lead to serious health complications. Nephrotoxicity is a concern in all clinical settings, but it is of special relevance among critically ill patients, and ~25% of the 100 most used drugs in intensive care units are potentially nephrotoxic [6]. Factors known to enhance drug nephrotoxicity include excessive dosing, ischemia, and hypovolemia. Here we aim to discuss whether the pathophysiological setting of the diabetic...
kidney affects the intrinsic susceptibility to AKI, with a particular focus on aminoglycoside-induced nephrotoxicity.

**Aminoglycoside-Induced AKI Primarily Targets the Proximal Tubule**

Aminoglycosides are widely used for infections by Gram-negative bacteria and bacterial endocarditis. These drugs are not metabolized in the body, have little protein binding (<10%), and are freely filtered in the glomeruli. Accumulation of the aminoglycoside gentamicin 24 h after intraperitoneal injection occurs primarily in lysosomes of the pars recta of proximal tubules via the endocytotic pathway [7]. Aminoglycosides bind to acidic membrane phospholipids, which can alter phospholipid metabolism and may initiate cellular uptake. The megalin-cubilin endocytic complex, which is localized to the brush border of the proximal tubule, reabsorbs >95% of the filtered albumin plus many other ligands (e.g. vitamin D-binding protein) and drugs, including aminoglycosides. Tubular aminoglycoside uptake is inhibited by the megalin antagonist RAP1 [8] and by maleate, which reduces ATP and causes shedding of megalin from the brush border surface, thus impairing receptor-mediated ligand uptake, including aminoglycosides [9, 10]. Importantly, renal accumulation of aminoglycosides is eliminated in mice lacking megalin [11] (unfortunately, the consequences in AKI have not been tested).

Molitoris and colleagues [12] revealed further details including retrograde trafficking of aminoglycosides through the secretory pathway and cytosolic release via the endoplasmatic reticulum, as well as the importance of subcellular distribution for nephrotoxicity [13]. Using in vivo multiphoton microscopy, the group further showed that the structural and functional changes in the proximal tubules affect first the brush border and lysosomes and subsequently the mitochondria [14]. Aminoglycoside-induced impairment of mitochondrial function reduces ATP generation. As a consequence, aminoglycosides inhibit transport along the nephron and typically induce a nonoliguric or even polyuric clinical manifestation (including proteinuria, enzymuria, aminoaciduria, glycosuria, and electrolyte alterations such as hypercalciuria and hypermagnesuria) [for a review, see 15]. Inhibition of proximal tubular NaCl reabsorption activates the TGF which, together with tubular obstruction and primary glomerular changes, lowers the GFR. In 1976, Thurau and Boylan [16] coined the term ‘acute renal success’, implicating the TGF-mediated GFR reduction in the protection of the body’s fluid and electrolyte homeostasis when tubular reabsorption is impaired. TGF resetting has been used as an argument that TGF may not sustain its primary effect on GFR in response to aminoglycosides [15]. However, we know from the pathophysiology of the diabetic kidney that the influence of proximal tubular hyperreabsorption on increases in the GFR (i.e. opposite scenario to AKI) is preserved despite TGF resetting and return of the operating point back to the steeper part of the TGF function [3].

**Experimental Diabetes Attenuates the Aminoglycoside Uptake and Nephrotoxicity**

Teixeira et al. [17] reported in 1982 that streptozotocin (STZ) type 1 diabetes in rats prevented the increase in serum creatinine and the decrease in creatinine clearance in response to gentamicin, which was associated with a reduced kidney uptake of the drug and the prevention of tubular necrosis. These findings were subsequently confirmed by multiple groups and shown to be reversed by insulin [18]. It was further shown that STZ diabetes reduces the renal expression of the megalin/cubilin endocytic complex [19, 20] via a mechanism that may include diabetes-induced TGF-β1 [21, 22] and/or matrix metalloproteinase activity, which is elevated in the diabetic kidney and urine [23], and can shed megalin from proximal tubular cell surfaces [24]. Notably, STZ-diabetes-mediated protection in rats or rabbits also includes other nephrotoxins such as cisplatin, mercuric chloride, S-1,2-dichlorovinyl-l-cysteine, and cephaloridine [for references, see 25]. Furthermore, STZ diabetes protects rats from the hepatotoxicity of normally lethal challenges, including thioacetamide, carbon tetrachloride, bromobenzene, and acetaminophen; this hepatoprotection was associated with early onset and robust compensatory hepatic tissue repair which depended on PPAR-α [26]. Similarly, diabetes-induced preplacement of tubular cells in the S-phase of the cell cycle has been proposed to mitigate S-1,2-dichlorovinyl-l-cysteine-initiated AKI by upregulating tissue repair [25]. In other words, hyperglycemia may be a sustained stressor that tonically activates tissue repair (‘preconditioning’), which facilitates the initial protective response to a nephrotoxin.

Elliott et al. [27] determined the inulin clearance in STZ-diabetic rats in response to gentamicin and confirmed an attenuated initial reduction in GFR associated with a lesser renal drug uptake and necrosis, as well as evidence for regeneration in diabetic kidneys even in the absence of ami-
noglycosides. In this regard, 4-month-old mice in which the tubular lumen downstream of the early proximal tubule is continuously exposed to enhanced glucose concentrations in the absence of hyperglycemia (due to gene knock-out of sodium glucose cotransporter 2) show enhanced renal protein expression of the cyclin-dependent kinase inhibitor p27 and the stress indicator hemoxygenase-1 [28]. Whether these mice show protection against aminoglycoside-induced nephrotoxicity has not been tested.

Do Diabetic Patients Have an Attenuated Renal Aminoglycoside Uptake and Are They Protected from Nephrotoxicity?

About 70% of the urinary proteome originates from kidney or genitourinary tissues. Thrailkill et al. [29] analyzed the proteins in 24-hour urine samples of individuals with type 1 diabetes with/without microalbuminuria in order to gain mechanistic insight into proteinuria. They found that microalbuminuria in type 1 diabetes was associated with enhanced urinary excretion of megalin and cubulin as well as enhanced urinary excretion of vitamin D-binding protein, and they proposed that aberrant shedding of megalin and cubulin in diabetes could contribute to albuminuria and to deficiency states of vitamins and hormones [29].

A systematic review and meta-analysis of 31 observational studies indicated that diabetes increased the risk of the development of AKI in critically ill patients by 58%, similar to the increase provoked by the application of a nephrotoxin [30]. In accordance, the UK General Practice Research Database found an adjusted hazard ratio of 2.5 for patients with type 2 diabetes to develop AKI [31]. Waikar et al. [32] reported that diabetes was identified as a risk factor for the development of AKI in 7 out of 18 studies that used multivariable models, including 1 study that focused on aminoglycoside-associated nephrotoxicity in the intensive care unit (table 1). More recently, Oliveira et al. [33] confirmed that diabetes doubled the risk for AKI when aminoglycoside treatment was initiated in the intensive care unit.

Table 1. Diabetes mellitus as a risk factor for the development of AKI

<table>
<thead>
<tr>
<th>Reference</th>
<th>Clinical setting</th>
<th>Patients with an AKI outcome, n (%)</th>
<th>AKI definition</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rich and Crecelius [35]</td>
<td>Risk factors for aminoglycoside-associated nephrotoxicity (ICUs)</td>
<td>183 (11)</td>
<td>Increase in SCr ≥0.5 mg/dl</td>
<td>Multivariable models identified diabetes as a risk factor</td>
</tr>
<tr>
<td>Lautin et al. [36]</td>
<td>Femoral arteriography</td>
<td>394 (22)</td>
<td>Increase in SCr &gt;0.3 mg/dl and 20% over baseline</td>
<td></td>
</tr>
<tr>
<td>McCullough et al. [37]</td>
<td>PCI</td>
<td>1,826 (0.77)</td>
<td>Need for dialysis</td>
<td></td>
</tr>
<tr>
<td>Rihal et al. [38]</td>
<td>PCI</td>
<td>7,586 (3.3)</td>
<td>Increase in SCr ≥0.5 mg/dl</td>
<td></td>
</tr>
<tr>
<td>Mehran et al. [39]</td>
<td>PCI</td>
<td>8,357 (13.1)</td>
<td>Increase in SCr ≥25% or ≥0.5 mg/dl</td>
<td></td>
</tr>
<tr>
<td>Thakar et al. [40]</td>
<td>CABG</td>
<td>33,217 (1.7)</td>
<td>Need for dialysis</td>
<td></td>
</tr>
<tr>
<td>Mehta et al. [41]</td>
<td>CABG</td>
<td>449,524 (1.4)</td>
<td>Need for dialysis</td>
<td></td>
</tr>
<tr>
<td>Oliveira et al. [33]</td>
<td>Starting aminoglycoside treatment in ICUs; baseline cGFR ≥30 ml/min/1.73 m²</td>
<td>360 (58)</td>
<td>Decrease in cGFR &gt;20%</td>
<td>Diabetes (OR 2.1), nephrotoxins (OR 1.6), iodinated contrast (OR 2.1)</td>
</tr>
<tr>
<td>Girman et al. [31]</td>
<td>UK General Practice Research Database</td>
<td>T2DM: 119,966 (0.2); nondiabetics: 1,794,516 (0.027)</td>
<td>READ diagnosis code for acute renal failure or from referral records/discharge summary</td>
<td>For patients with type 2 diabetes: adjusted hazard ratio 2.5, 95% CI 2.2–2.7</td>
</tr>
</tbody>
</table>

CABG = Coronary artery bypass grafting; cGFR = calculated GFR; ICU = intensive care unit; OR = odds ratio; PCI = percutaneous coronary intervention; SCr = serum creatinine; T2DM = type 2 diabetes mellitus. Based in part on Waikar et al. [42].
Senescence is a tumor suppressor mechanism that causes cell hypertrophy and senescence also alters the cellular phenotype, which has been proposed to be linked to unusual responses in the diabetic kidney like the salt paradox but also to the release of proinflammatory factors and thereby may contribute to the development of diabetic nephropathy [2, 3]. Further studies are needed to determine whether senescence enhances the susceptibility of the diabetic kidney to AKI.

**Conclusions and Perspectives**

Diabetes can attenuate the nephrotoxicity to aminoglycosides and other nephrotoxins in rodents. The involved mechanisms include inhibition of the megalin-mediated aminoglycoside uptake in the proximal tubule by diabetes-induced TGF-β and/or matrix metalloproteinase as well as facilitation of cell repair, possibly due to continuous activation of regenerative mechanisms. We need to better understand the molecular triggers and the effectors of these regenerative mechanisms. We also need to further explore the finding of impaired recovery of GFR in diabetic rodents beyond 14 days of aminoglycoside treatment. There is some evidence for downregulation of megalin in diabetic patients with microalbuminuria. However, multi-variable models for the development of AKI in humans have identified diabetes as a risk factor also in the setting of aminoglycoside application, indicating that isolated induction of diabetes in otherwise healthy young adult rodents may not capture the influence of diabetes in the setting of critically ill and often elderly patients. It remains to be determined whether patients without microalbuminuria are at greater risk than patients with microalbuminuria, assuming that the latter in part indicates a reduced megalin/cubulin function and, therefore, aminoglycoside uptake. Advanced diabetic kidney injury, senescence, ischemia, inflammation, and enhanced oxidative stress in the diabetic kidney are expected to increase nephrotoxicity. Considering the established strong association in diabetes between episodes of AKI and the cumulative risk for developing advanced CKD, we hypothesize that diabetic tubular growth and the associated molecular signature set up the development of diabetic nephropathy and advanced CKD in part by increasing the susceptibility to AKI (fig. 1). In other words, diabetic patients with larger kidneys are expected to show the greatest susceptibility to the development of AKI. Further studies are needed to test this hypothesis. Better strategies are needed to reduce AKI in diabetic patients to help reduce the growing burden of end-stage renal disease.

**Acknowledgments**

This work was supported by NIH grants R01DK56248 and R01HL94728, the UAB-UCSD O’Brien Center of Acute Kidney Injury (NIH P30 DK079337), and the Department of Veterans Affairs.

**Disclosure Statement**

Within the past 12 months, Dr. Vallon has received research grant support for basic science studies from Boehringer Ingelheim Pharma GmbH & Co. KG and AstraZeneca.

**References**


